Literature DB >> 11281944

An association between clozapine-induced agranulocytosis in schizophrenics and HLA-DQB1*0201.

Avraham Amar1, Ronnen H. Segman, Shlomo Shtrussberg, Leny Sherman, Cilly Safirman, Bernard Lerer, Chaim Brautbar.   

Abstract

A group of 18 Israeli, clozapine-treated, schizophrenia patients underwent molecular and serological HLA typing in order to determine whether the major histocompatibility complex is associated with the development of clozapine-induced agranulocytosis. While under treatment with clozapine, 2 of the 18 patients developed agranulocytosis (total white blood cell count <3000/mm(3) and absolute polymorphonuclear count <500/mm(3)) and 3 developed granulocytopenia (total white blood cell count <3500/mm(3) and absolute polymorphonuclear count <1000/mm(3)). HLA-DQB1*0201 was present in all five patients who developed agranulocytosis or granulocytopenia (5/5; 100%), but in only 54% (7/13) of the patients who did not develop those complications. These findings indicate that DQB1*0201 or a gene located nearby could be involved in clozapine-induced agranulocytosis.

Entities:  

Year:  1998        PMID: 11281944     DOI: 10.1017/S1461145798001023

Source DB:  PubMed          Journal:  Int J Neuropsychopharmacol        ISSN: 1461-1457            Impact factor:   5.176


  12 in total

Review 1.  The promise and reality of pharmacogenetics in psychiatry.

Authors:  Peter P Zandi; Jennifer T Judy
Journal:  Psychiatr Clin North Am       Date:  2010-03

Review 2.  Pharmacogenetics of response to antipsychotics in patients with schizophrenia.

Authors:  Maria J Arranz; Margarita Rivera; Janet C Munro
Journal:  CNS Drugs       Date:  2011-11-01       Impact factor: 5.749

Review 3.  Genetics of antipsychotic-induced side effects and agranulocytosis.

Authors:  Nabilah I Chowdhury; Gary Remington; James L Kennedy
Journal:  Curr Psychiatry Rep       Date:  2011-04       Impact factor: 5.285

Review 4.  More than 25 years of genetic studies of clozapine-induced agranulocytosis.

Authors:  S A J de With; S L Pulit; W G Staal; R S Kahn; R A Ophoff
Journal:  Pharmacogenomics J       Date:  2017-04-18       Impact factor: 3.550

5.  Pharmacogenetics of Antipsychotic Treatment in Schizophrenia.

Authors:  Samar S M Elsheikh; Daniel J Müller; Jennie G Pouget
Journal:  Methods Mol Biol       Date:  2022

Review 6.  Clinically available pharmacogenomics tests.

Authors:  D A Flockhart; T Skaar; D S Berlin; T E Klein; A T Nguyen
Journal:  Clin Pharmacol Ther       Date:  2009-04-15       Impact factor: 6.875

7.  Clozapine-induced blood dyscrasias in Saudi Arab patients.

Authors:  Norah O Abanmy; Afnan Al-Jaloud; Aisha Al-Jabr; Rana Al-Ruwaisan; Walaa Al-Saeed; Solafa Fatani
Journal:  Int J Clin Pharm       Date:  2014-06-12

Review 8.  Pharmacogenetics of antipsychotics: recent progress and methodological issues.

Authors:  Jian-Ping Zhang; Anil K Malhotra
Journal:  Expert Opin Drug Metab Toxicol       Date:  2012-12-01       Impact factor: 4.481

Review 9.  Clozapine Pharmacogenetic Studies in Schizophrenia: Efficacy and Agranulocytosis.

Authors:  Shusuke Numata; Hidehiro Umehara; Tetsuro Ohmori; Ryota Hashimoto
Journal:  Front Pharmacol       Date:  2018-09-26       Impact factor: 5.810

Review 10.  Impact of New Genomic Technologies on Understanding Adverse Drug Reactions.

Authors:  Simran D S Maggo; Ruth L Savage; Martin A Kennedy
Journal:  Clin Pharmacokinet       Date:  2016-04       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.